Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

<p>Phosphorylation of histone H2AX as a marker of dsDNA breaks induced from cell internalization of Dato-DΧd. <b>A,</b> TROP2-negative cell line END(K)34 does not show statistically significant difference in p-H2AX MFI when treated with 5 μg/mL Dato-DΧd vs. when treated with 5 μg/m...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
מחבר ראשי: Niccolò G. Santin (22229756) (author)
מחברים אחרים: Namrata Sethi (21290758) (author), Stefania Bellone (15122334) (author), Cem Demirkiran (17533603) (author), Victoria M. Ettorre (21290752) (author), Michelle Greenman (18472858) (author), Blair McNamara (17533585) (author), Natalia Buza (17533594) (author), Tobias M.P. Hartwich (15122337) (author), Luca Palmieri (22229759) (author), Domenica Lorusso (22229762) (author), Alessandro D. Santin (15122349) (author)
יצא לאור: 2025
נושאים:
Cancer
Cancer Detection and Diagnosis
Therapeutic Research and Development
Biological Agents & Therapies
Biomarkers
Drug Targets
Gynecological Cancers
Endometrial cancer
Prognostic Biomarkers
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים